US865A
(en)
|
|
1838-08-01 |
|
Improvement in fire-arms |
US7399A
(en)
|
|
1850-05-28 |
|
charles payne |
CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
TW254946B
(sl)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
UA41909C2
(uk)
|
1994-07-22 |
2001-10-15 |
Елі Ліллі Енд Компані |
Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP4009681B2
(ja)
|
1995-11-07 |
2007-11-21 |
キリンファーマ株式会社 |
血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
AU763669B2
(en)
|
1998-09-29 |
2003-07-31 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
JP2003519698A
(ja)
|
2000-01-07 |
2003-06-24 |
トランスフォーム ファーマスーティカルズ,インコーポレイテッド |
多様な固体形態のハイスループットでの形成、同定および分析
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
WO2002013802A2
(en)
|
2000-08-11 |
2002-02-21 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
DE60228699D1
(de)
|
2001-04-06 |
2008-10-16 |
Wyeth Corp |
Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
|
SG153647A1
(en)
|
2001-06-01 |
2009-07-29 |
Wyeth Corp |
Antineoplastic combinations
|
ZA200603888B
(en)
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
NZ533118A
(en)
|
2001-11-27 |
2006-07-28 |
Wyeth Corp |
3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
EP1803821B1
(en)
|
2002-06-05 |
2012-02-29 |
Cedars-Sinai Medical Center |
Methods for managing kinase inhibitor therapy
|
US20060094674A1
(en)
|
2002-07-05 |
2006-05-04 |
Neel Benjamin G |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
ES2279407T3
(es)
|
2003-04-22 |
2007-08-16 |
Wyeth |
Combinaciones antineoplasicas.
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
ME00294B
(me)
|
2003-07-23 |
2011-05-10 |
Bayer Pharmaceuticals Corp |
Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
RU2006106267A
(ru)
|
2003-08-01 |
2006-07-27 |
Уайт Холдингз Корпорейшн (Us) |
Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
|
CN1835923A
(zh)
|
2003-08-19 |
2006-09-20 |
惠氏控股公司 |
制备4-氨基-3-喹啉腈的方法
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
MXPA06002846A
(es)
|
2003-09-15 |
2006-06-14 |
Wyeth Corp |
Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa.
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
WO2005044091A2
(en)
|
2003-11-05 |
2005-05-19 |
Board Of Regents, The University Of Texas System |
Diagnostic and therapeutic methods and compositions involving pten and breast cancer
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
EP2439285B1
(en)
|
2004-03-31 |
2019-05-08 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
WO2006008526A2
(en)
|
2004-07-23 |
2006-01-26 |
Astrazeneca Ab |
Method of predicting the responsiveness oa a tumor to erbb receptor drugs
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
TW200626610A
(en)
|
2004-10-13 |
2006-08-01 |
Wyeth Corp |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
US10603314B2
(en)
|
2005-02-03 |
2020-03-31 |
The General Hospital Corporation |
Method for treating gefitinib resistant cancer
|
WO2006081985A1
(en)
*
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
WO2006090930A1
(ja)
|
2005-02-28 |
2006-08-31 |
Eisai R & D Management Co., Ltd. |
スルホンアミド化合物の新規併用
|
ES2441019T3
(es)
|
2005-03-09 |
2014-01-31 |
Abbott Laboratories |
Métodos de diagnóstico para identificar pacientes candidatos para el tratamiento con trastuzumab
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20060235006A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
WO2006113151A2
(en)
|
2005-04-14 |
2006-10-26 |
Wyeth |
Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
|
WO2006116016A2
(en)
|
2005-04-21 |
2006-11-02 |
The Regents Of The University Of California |
Molecular determinants of egfr kinase inhibitor response in glioblastoma
|
AU2006241113B2
(en)
|
2005-04-28 |
2011-08-18 |
Wyeth |
Micronized tanaproget, compositions, and methods of preparing the same
|
BRPI0609957A2
(pt)
|
2005-05-12 |
2010-05-11 |
Pfizer |
uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
|
JP2008542267A
(ja)
|
2005-05-25 |
2008-11-27 |
ワイス |
3−シアノ−キノリンと、それにより製造される中間体とを調製する方法
|
TW200716557A
(en)
|
2005-05-25 |
2007-05-01 |
Wyeth Corp |
Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
CA2612960A1
(en)
|
2005-07-15 |
2007-01-25 |
Wyeth |
Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
WO2007039705A1
(en)
|
2005-10-05 |
2007-04-12 |
Astrazeneca Uk Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
WO2007050495A2
(en)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
AR058505A1
(es)
|
2005-11-04 |
2008-02-06 |
Wyeth Corp |
Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
|
JP2009514870A
(ja)
|
2005-11-04 |
2009-04-09 |
ワイス |
mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
|
EP2340837B1
(en)
|
2005-11-11 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
PL1951274T3
(pl)
|
2005-11-24 |
2010-05-31 |
Aicuris Gmbh & Co Kg |
Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
|
JP2007145745A
(ja)
*
|
2005-11-25 |
2007-06-14 |
Osaka Univ |
変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
|
WO2007075794A2
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
KR101292508B1
(ko)
*
|
2006-04-07 |
2013-08-01 |
노파르티스 아게 |
백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 c-src 억제제의 용도
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
CN103424541B
(zh)
|
2006-05-18 |
2018-01-30 |
分子压型学会股份有限公司 |
确定针对病状的个性化医疗介入的系统和方法
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
ES2427924T3
(es)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
Biomarcador IGFBP2
|
US8877764B2
(en)
|
2006-09-18 |
2014-11-04 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring EGFR mutations
|
CA2664697A1
(en)
|
2006-09-28 |
2008-04-10 |
Follica, Inc. |
Methods, kits, and compositions for generating new hair follicles and growing hair
|
US20090317456A1
(en)
|
2006-10-13 |
2009-12-24 |
Medigene Ag |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
US20110262525A1
(en)
|
2006-12-13 |
2011-10-27 |
Schering Corporation |
Methods of treatment
|
EP2121018A2
(en)
|
2006-12-13 |
2009-11-25 |
Schering Corporation |
Treating cancer with anti-igf1r antibody 19d12=sch 717454
|
WO2008076143A1
(en)
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
NZ577798A
(en)
|
2006-12-21 |
2012-04-27 |
Vertex Pharma |
5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
CL2008000095A1
(es)
|
2007-01-12 |
2008-05-16 |
Wyeth Corp |
Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
|
MX2009007987A
(es)
|
2007-01-25 |
2010-03-01 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
PE20081734A1
(es)
|
2007-02-01 |
2009-01-19 |
Takeda Pharmaceutical |
Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
WO2008127710A2
(en)
|
2007-04-13 |
2008-10-23 |
Dana Farber Cancer Institute |
Methods for treating cancer resistant to erbb therapeutics
|
CA2684265A1
(en)
|
2007-04-19 |
2008-10-30 |
Wellstat Biologics Corporation |
Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
SI2200431T1
(sl)
|
2007-09-10 |
2016-10-28 |
Boston Biomedical, Inc. |
Sestave in metode za zdravljenje raka
|
EP2205076A4
(en)
|
2007-09-24 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
EP2212432A4
(en)
|
2007-10-22 |
2011-10-19 |
Schering Corp |
COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
|
AU2008325219A1
(en)
|
2007-11-05 |
2009-05-14 |
Puretech Ventures |
Methods, kits, and compositions for administering pharmaceutical compounds
|
US20110091524A1
(en)
|
2007-12-18 |
2011-04-21 |
Yan Wang |
Biomarkers for sensitivity to anti-igf1r therapy
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
MX2010009140A
(es)
|
2008-02-25 |
2010-12-20 |
Prometheus Lab Inc |
Seleccion de farmacos para terapia de cancer de mama utilizando matrices basadas en anticuerpos.
|
US20100081632A1
(en)
|
2008-03-06 |
2010-04-01 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
MX2010010480A
(es)
|
2008-03-25 |
2010-10-15 |
Schering Corp |
Metodos de tratamiento o prevencion del cancer colorrectal.
|
WO2009121031A1
(en)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
WO2009126662A1
(en)
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
|
CN102066398B
(zh)
|
2008-04-18 |
2014-09-10 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
|
MX339476B
(es)
|
2008-04-18 |
2016-05-27 |
Reata Pharmaceuticals Inc |
Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
|
WO2009146216A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
ES2703274T3
(es)
|
2008-04-18 |
2019-03-07 |
Reata Pharmaceuticals Inc |
Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
|
NZ588709A
(en)
|
2008-04-18 |
2012-11-30 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: triterpenoid oleanolic acid derivatives with saturation in the c-ring
|
CA2722992A1
(en)
|
2008-05-05 |
2009-11-12 |
Schering Corporation |
Sequential administration of chemotherapeutic agents for treatment of cancer
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
KR20110010787A
(ko)
|
2008-06-17 |
2011-02-07 |
와이어쓰 엘엘씨 |
Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물
|
EP2309860B1
(en)
|
2008-07-22 |
2014-01-08 |
Trustees of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
EP3175853B1
(en)
|
2008-08-04 |
2023-11-01 |
Wyeth LLC |
Antineoplastic combinations of neratinib and capecitabine
|
US20100069340A1
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
EP3075864A1
(en)
|
2008-10-14 |
2016-10-05 |
Caris MPI, Inc. |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
KR20110086844A
(ko)
|
2008-11-07 |
2011-08-01 |
엔즌 파마슈티칼스, 인코포레이티드 |
Erbb-3(her3)-선택적 조합 요법
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
KR20110113648A
(ko)
|
2009-02-04 |
2011-10-17 |
바이파 사이언스 인코포레이티드 |
Parp 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
BRPI1011505A2
(pt)
|
2009-03-11 |
2016-03-22 |
Auckland Uniservices Ltd |
formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
|
JP5992325B2
(ja)
|
2009-04-06 |
2016-09-14 |
ワイス・エルエルシー |
乳癌のための、ネラチニブを活用する治療計画
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
WO2010129053A2
(en)
|
2009-05-05 |
2010-11-11 |
Dana Farber Cancer Institute |
Egfr inhibitors and methods of treating disorders
|
CA2766067A1
(en)
|
2009-07-02 |
2011-01-06 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
US20120135952A1
(en)
|
2009-07-17 |
2012-05-31 |
Hanall Biopharma Co., Ltd. |
Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
|
KR101211227B1
(ko)
|
2009-08-25 |
2012-12-11 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025267A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025269A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
EP2470212A4
(en)
|
2009-10-01 |
2013-12-04 |
Csl Ltd |
METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
|
EP3566697A1
(en)
|
2009-11-09 |
2019-11-13 |
Wyeth LLC |
Tablet formulations of neratinib maleate
|
WO2011056741A2
(en)
|
2009-11-09 |
2011-05-12 |
Wyeth Llc |
Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
|
PT2719708T
(pt)
|
2009-11-13 |
2018-01-16 |
Daiichi Sankyo Europe Gmbh |
Material e métodos para tratamento ou prevenção de doenças associadas a her-3
|
EP2509592A1
(en)
|
2009-12-07 |
2012-10-17 |
Boehringer Ingelheim International GmbH |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
CA2783743C
(en)
|
2009-12-11 |
2022-10-04 |
Wyeth Llc |
Phosphatidylinositol-3-kinase pathway biomarkers
|
JP6126382B2
(ja)
|
2010-01-13 |
2017-05-10 |
ワイス・エルエルシー |
腫瘍を正確に識別し、かつPAN‐ErbB阻害剤に対する薬物応答を予測するPTENタンパク質発現におけるカットポイント
|